Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitor
Autor(a) principal: | |
---|---|
Data de Publicação: | 2000 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://dx.doi.org/10.1038/sj.bjp.0703362 http://repositorio.unifesp.br/handle/11600/26331 |
Resumo: | 1 the pharmacological activity of phenylacetyl-Phe-Ser-Arg-N-(2,4-dinitrophenyl)-ethylenediamine (TKI), a tissue kallikrein specific inhibitor, was assessed using models of nociception and inflammation in mice.2 Injection of TKI (13.6-136 mu mol kg(-1), i.p. or 41-410 mu mol kg(-1), s.c.) produced a dose-related inhibition of the acetic acid-induced writhes (by 37 to 85% or 34 to 80%, respectively). the antinociceptive activity of TKI (41 mu mol kg(-1), i.p.) was maximal after 30 min injection and lasted for 120 min. the effect was unaltered by pretreatment with naloxone (8.2 mu mol kg(-1), s.c.) or bilateral adrenalectomy.3 TRI (41 and 136 mu mol kg(-1), i.p.) produced a dose-related decrease of the late phase of formalin-induced nociception by 79 and 98%, respectively. At 136 mu mol kg(-1), i.p., TKI also shortened the duration of paw licking in the early phase by 69%. TKI (41 and 136 mu mol kg(-1), i.p.) also reduced the capsaicin-induced nociceptive response (by 51 to 79%).4 TKI (41 pmol kg(-1), i.p. or 410 mu mol kg(-1), s.c.) reduced the oedematogenic response, from the second to the fifth hour after carrageenin injection by 36 to 30% or by 47 to 39%, respectively.5 Pretreatment with TKI (41 mu mol kg(-1), i.p.) reduced the capsaicin-induced neurogenic inflammation in the mouse ear by 54%.6 It is concluded that TKI presents antinociceptive and antiinflammatory activities mediated by inhibition of kinin formation by tissue kallikrein in mice. the results also indicate that the tissue kallikrein-dependent pathway contributes to kinin generation in nociceptive and inflammatory processes in mice. |
id |
UFSP_122003536123217729ed8e7eb1b61ff3 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/26331 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitortissue kallikrein inhibitorkininsnociceptioninflammation1 the pharmacological activity of phenylacetyl-Phe-Ser-Arg-N-(2,4-dinitrophenyl)-ethylenediamine (TKI), a tissue kallikrein specific inhibitor, was assessed using models of nociception and inflammation in mice.2 Injection of TKI (13.6-136 mu mol kg(-1), i.p. or 41-410 mu mol kg(-1), s.c.) produced a dose-related inhibition of the acetic acid-induced writhes (by 37 to 85% or 34 to 80%, respectively). the antinociceptive activity of TKI (41 mu mol kg(-1), i.p.) was maximal after 30 min injection and lasted for 120 min. the effect was unaltered by pretreatment with naloxone (8.2 mu mol kg(-1), s.c.) or bilateral adrenalectomy.3 TRI (41 and 136 mu mol kg(-1), i.p.) produced a dose-related decrease of the late phase of formalin-induced nociception by 79 and 98%, respectively. At 136 mu mol kg(-1), i.p., TKI also shortened the duration of paw licking in the early phase by 69%. TKI (41 and 136 mu mol kg(-1), i.p.) also reduced the capsaicin-induced nociceptive response (by 51 to 79%).4 TKI (41 pmol kg(-1), i.p. or 410 mu mol kg(-1), s.c.) reduced the oedematogenic response, from the second to the fifth hour after carrageenin injection by 36 to 30% or by 47 to 39%, respectively.5 Pretreatment with TKI (41 mu mol kg(-1), i.p.) reduced the capsaicin-induced neurogenic inflammation in the mouse ear by 54%.6 It is concluded that TKI presents antinociceptive and antiinflammatory activities mediated by inhibition of kinin formation by tissue kallikrein in mice. the results also indicate that the tissue kallikrein-dependent pathway contributes to kinin generation in nociceptive and inflammatory processes in mice.Universidade Federal de São Paulo, Escola Paulista Med, Dept Pharmacol, Nat Prod Sect, BR-04044020 São Paulo, SP, BrazilUniversidade Federal de São Paulo, Escola Paulista Med, Dept Biophys, BR-04044020 São Paulo, SP, BrazilUniversidade Federal de São Paulo, Escola Paulista Med, Dept Pharmacol, Nat Prod Sect, BR-04044020 São Paulo, SP, BrazilUniversidade Federal de São Paulo, Escola Paulista Med, Dept Biophys, BR-04044020 São Paulo, SP, BrazilWeb of ScienceNature Publishing GroupUniversidade Federal de São Paulo (UNIFESP)Emim, José ADSouccar, Caden [UNIFESP]Castro, Maria SDGodinho, Rosely Oliveira [UNIFESP]Cezari, Maria HSJuliano, Luiz [UNIFESP]Lapa, Antonio José [UNIFESP]2016-01-24T12:31:07Z2016-01-24T12:31:07Z2000-07-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion1099-1107http://dx.doi.org/10.1038/sj.bjp.0703362British Journal of Pharmacology. Basingstoke: Nature Publishing Group, v. 130, n. 5, p. 1099-1107, 2000.10.1038/sj.bjp.07033620007-1188http://repositorio.unifesp.br/handle/11600/26331WOS:000088067100018engBritish Journal of Pharmacologyinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2023-05-18T14:58:13Zoai:repositorio.unifesp.br/:11600/26331Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652023-05-18T14:58:13Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitor |
title |
Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitor |
spellingShingle |
Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitor Emim, José AD tissue kallikrein inhibitor kinins nociception inflammation |
title_short |
Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitor |
title_full |
Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitor |
title_fullStr |
Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitor |
title_full_unstemmed |
Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitor |
title_sort |
Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitor |
author |
Emim, José AD |
author_facet |
Emim, José AD Souccar, Caden [UNIFESP] Castro, Maria SD Godinho, Rosely Oliveira [UNIFESP] Cezari, Maria HS Juliano, Luiz [UNIFESP] Lapa, Antonio José [UNIFESP] |
author_role |
author |
author2 |
Souccar, Caden [UNIFESP] Castro, Maria SD Godinho, Rosely Oliveira [UNIFESP] Cezari, Maria HS Juliano, Luiz [UNIFESP] Lapa, Antonio José [UNIFESP] |
author2_role |
author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) |
dc.contributor.author.fl_str_mv |
Emim, José AD Souccar, Caden [UNIFESP] Castro, Maria SD Godinho, Rosely Oliveira [UNIFESP] Cezari, Maria HS Juliano, Luiz [UNIFESP] Lapa, Antonio José [UNIFESP] |
dc.subject.por.fl_str_mv |
tissue kallikrein inhibitor kinins nociception inflammation |
topic |
tissue kallikrein inhibitor kinins nociception inflammation |
description |
1 the pharmacological activity of phenylacetyl-Phe-Ser-Arg-N-(2,4-dinitrophenyl)-ethylenediamine (TKI), a tissue kallikrein specific inhibitor, was assessed using models of nociception and inflammation in mice.2 Injection of TKI (13.6-136 mu mol kg(-1), i.p. or 41-410 mu mol kg(-1), s.c.) produced a dose-related inhibition of the acetic acid-induced writhes (by 37 to 85% or 34 to 80%, respectively). the antinociceptive activity of TKI (41 mu mol kg(-1), i.p.) was maximal after 30 min injection and lasted for 120 min. the effect was unaltered by pretreatment with naloxone (8.2 mu mol kg(-1), s.c.) or bilateral adrenalectomy.3 TRI (41 and 136 mu mol kg(-1), i.p.) produced a dose-related decrease of the late phase of formalin-induced nociception by 79 and 98%, respectively. At 136 mu mol kg(-1), i.p., TKI also shortened the duration of paw licking in the early phase by 69%. TKI (41 and 136 mu mol kg(-1), i.p.) also reduced the capsaicin-induced nociceptive response (by 51 to 79%).4 TKI (41 pmol kg(-1), i.p. or 410 mu mol kg(-1), s.c.) reduced the oedematogenic response, from the second to the fifth hour after carrageenin injection by 36 to 30% or by 47 to 39%, respectively.5 Pretreatment with TKI (41 mu mol kg(-1), i.p.) reduced the capsaicin-induced neurogenic inflammation in the mouse ear by 54%.6 It is concluded that TKI presents antinociceptive and antiinflammatory activities mediated by inhibition of kinin formation by tissue kallikrein in mice. the results also indicate that the tissue kallikrein-dependent pathway contributes to kinin generation in nociceptive and inflammatory processes in mice. |
publishDate |
2000 |
dc.date.none.fl_str_mv |
2000-07-01 2016-01-24T12:31:07Z 2016-01-24T12:31:07Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1038/sj.bjp.0703362 British Journal of Pharmacology. Basingstoke: Nature Publishing Group, v. 130, n. 5, p. 1099-1107, 2000. 10.1038/sj.bjp.0703362 0007-1188 http://repositorio.unifesp.br/handle/11600/26331 WOS:000088067100018 |
url |
http://dx.doi.org/10.1038/sj.bjp.0703362 http://repositorio.unifesp.br/handle/11600/26331 |
identifier_str_mv |
British Journal of Pharmacology. Basingstoke: Nature Publishing Group, v. 130, n. 5, p. 1099-1107, 2000. 10.1038/sj.bjp.0703362 0007-1188 WOS:000088067100018 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
British Journal of Pharmacology |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
1099-1107 |
dc.publisher.none.fl_str_mv |
Nature Publishing Group |
publisher.none.fl_str_mv |
Nature Publishing Group |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268349736026112 |